The drug manufacturer expects $4.3 billion to $4.5 billion in fiscal 2024 revenue. Analysts has been forecasting $4.2 billion.
Catalent issued a healthy outlook for fiscal 2024 revenue and announced a settlement with activist investor Elliott Investment Management that would include a review of the drug manufacturer’s business strategy.
Catalent earnings 9 cents a share for the fourth fiscal quarter ended in June. Analysts had been expecting 11 cents. Revenue of $1.07 billion exceeded the $1.05 billion analysts expected but dropped 17% from the year-earlier quarter.Catalent said it expects $4.3 billion to $4.5 billion in fiscal 2024 revenue, higher than analysts’ estimates of $4.2 billion.
Catalent also said it reached a settlement with activist investor Elliott. The deal includes adding four new independent directors to the board as well as the creation of a committee that would review the company’s strategy.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Exclusive-Catalent nears settlement with Elliott for board seats -sources By ReutersExclusive-Catalent nears settlement with Elliott for board seats -sources
Leer más »
Exclusive: Catalent to settle with Elliott, explore options -sourcesCatalent Inc is close to reaching a settlement with activist investor Elliott Investment Management which will include new directors and a pledge to review strategic alternatives such as the sale of the company, sources familiar with the matter said on Monday.
Leer más »
Catalent reaches settlement with Elliot to explore strategic reviewCatalent Inc said on Tuesday it has reached a settlement with activist investor Elliot Investment Management, agreeing to add four new directors to its board and to conduct a 'strategic review'.
Leer más »
Catalent stock jumps after cooperation agreement with activist investor Elliott InvestmentShares of Catalent Inc. jumped 4.1% in premarket trading Tuesday, after the maker of products used by drug makers and consumer health companies announced an...
Leer más »
Gold Road posts solid resultsGold miner Gold Road Resources has closed a strong first half to June, with gold sales and revenue up. Gold sales during the six months under review reached 80 115 oz, up from the 79 606 oz in the previous corresponding period, with production benefitting from record throughput rates at the Gruyere joint venture, in Western Australia.
Leer más »
Ramelius posts solid yearGold miner Ramelius Resources has reported a 396% increase to its statutory net profits after tax for the full year ended June. The gold miner reported statutory net profits after tax of A$61.6-million, up from the a$12.4-million reported in the 2022 financial year, due in part to lower non-cash impairments made to the Edna May operation last year.
Leer más »